Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)32 enrolled

Overview

Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

OBJECTIVES: I. Determine the efficacy of fenretinide, in terms of complete and partial response rates, duration of response, and survival, in patients with recurrent small cell lung cancer. II. Determine the toxicity of this regimen in these patients. III. Correlate the induction of apoptosis or the expression of molecular mediators of apoptosis in tumor cells with response rates, response duration, and survival in patients treated with this regimen. OUTLINE: This is an open-label, multicenter study. Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lung Cancer

Interventions

fenretinideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) after platinum-containing chemotherapy regimen with or without thoracic radiotherapy * Limited stage or extensive stage SCLC * Measurable disease * At least 20 mm by conventional techniques OR * At least 10 mm with spiral CT scan * No pleural effusions, bone metastases, brain metastases, or abnormal radionucleotide scans as sole evidence of disease * No symptomatic or uncontrolled brain or leptomeningeal disease * Previously treated brain metastases allowed if neurologically stable PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Zubrod 0-2 Hematopoietic: * WBC at least 2,500/mm\^3 * Platelet count at least 70,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No symptomatic heart disease * No myocardial infarction within the past 6 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception for 1 month before, during, and for 2 months after study * No pre-existing retinal degenerative disease (e.g., retinitis pigmentosa or associated disorders) * No other serious concurrent illness * No other malignancy within the past 5 years except localized nonmelanoma skin cancer or carcinoma in situ PRIOR CONCURRENT THERAPY: Chemotherapy: * At least 3 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens Endocrine therapy: * Concurrent steroids allowed at stable dose Radiotherapy: * No prior radiotherapy to study lesions Other: * At least 3 weeks since prior systemic retinoid or carotenoid therapy * No concurrent anticonvulsants

Locations (2)

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.